We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-4.59%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$99.1M
AUM Growth
-$6.37M
Cap. Flow
+$1.03M
Cap. Flow %
1.04%
Top 10 Hldgs %
58.86%
Holding
65
New
16
Increased
6
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$3.23M
2
OCRX
Ocera Therapeutics, Inc.
OCRX
+$2.97M
3
AERI
Aerie Pharmaceuticals
AERI
+$2.87M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$1.54M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$989K

Top Sells

Rank Stock Value
1
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$7.02M
2
VXRT
Vaxart
VXRT
+$2.08M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$1.47M
4
KERX
Keryx Biopharmaceuticals Inc
KERX
+$1.42M
5
GLMD icon
Galmed Pharmaceuticals
GLMD
+$677K

Sector Composition

Rank Sector Weight
1 Healthcare 55.76%
2 Financials 1.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELOS
26
DELISTED
Syneron Medical Ltd
ELOS
$911K 0.92%
90,947
– –
BLUE
27
DELISTED
bluebird bio
BLUE
$897K 0.9%
+1,930
New +$891K
CUTR
28
DELISTED
Cutera, Inc.
CUTR
$896K 0.9%
88,694
– –
AFMD
29
DELISTED
Affimed
AFMD
$756K 0.76%
+12,000
New +$749K
BCRX icon
30
BioCryst Pharmaceuticals
BCRX
$2.42B
$747K 0.75%
+76,400
New +$936K
EXAC
31
DELISTED
Exactech Inc
EXAC
$724K 0.73%
31,636
– –
VCEL icon
32
Vericel Corp
VCEL
$2.38B
$681K 0.69%
+238,900
New +$790K
CYTR
33
DELISTED
CytRx Corp
CYTR
$572K 0.58%
37,500
– –
AMPE
34
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$530K 0.53%
500
-4,170
-89% -$7.02M
CDNA icon
35
CareDx
CDNA
$1.83B
$525K 0.53%
+75,000
New +$721K
ICPT
36
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$473K 0.48%
2,000
– –
CASC
37
DELISTED
Cascadian Therapeutics, Inc.
CASC
$413K 0.42%
+35,829
New +$547K
SRGA
38
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$411K 0.41%
2,864
-2,705
-49% -$392K
FATE icon
39
Fate Therapeutics
FATE
$275M
$387K 0.39%
75,930
– –
MASI
40
DELISTED
Masimo
MASI
$372K 0.38%
17,500
– –
SCYX icon
41
SCYNEXIS
SCYX
$37.4M
$370K 0.37%
625
– –
APEN
42
DELISTED
Apollo Endosurgery, Inc.
APEN
$362K 0.37%
1,335
-29
-2% -$7.88K
GYRE icon
43
Gyre Therapeutics
GYRE
$629M
$339K 0.34%
+170
New +$420K
QURE icon
44
uniQure
QURE
$2.78B
$296K 0.3%
+32,000
New +$351K
AKTX
45
Akari Therapeutics
AKTX
$14.4M
$268K 0.27%
5
– –
ACHN
46
DELISTED
Achillion Pharmaceuticals
ACHN
$259K 0.26%
+26,000
New +$241K
LMNS
47
DELISTED
LUMENIS LTD CL B ORD SHS (ISR)
LMNS
$259K 0.26%
29,018
+19,540
+206% +$179K
BLFS icon
48
BioLife Solutions
BLFS
$1.54B
$244K 0.25%
116,279
– –
IPCI
49
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$219K 0.22%
+7,279
New +$210K
CRIS icon
50
Curis
CRIS
$9.71M
$212K 0.21%
75
– –
1
2
3

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, DAFNA Capital Management held 65 positions worth $99.1M, down 6% from $106M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

DAFNA Capital Management's Q3 2014 filing shows 16 new, 6 increased, 7 reduced and 6 closed positions. Its largest new stake was AUSPEX PHARMACEUTICALS INC COM STK (DE): 152,002 shares worth $3.9M. The largest sale was Ampio Pharmaceuticals Inc., an estimated $7.02M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 70% a quarter earlier, followed by Financials.

  • DAFNA Capital Management's largest Q3 2014 buy was AUSPEX PHARMACEUTICALS INC COM STK (DE): 152,002 shares worth $3.9M.
  • DAFNA Capital Management added most to Ocera Therapeutics, Inc. in Q3 2014, an estimated $2.97M increase.
  • DAFNA Capital Management's biggest Q3 2014 reduction was Ampio Pharmaceuticals Inc., cutting an estimated $7.02M.
  • DAFNA Capital Management fully exited Vaxart in Q3 2014, selling an estimated $2.08M.
  • DAFNA Capital Management's ten largest holdings make up 59% of its $99.1M portfolio in Q3 2014.
  • DAFNA Capital Management opened 16 new positions and closed 6 in Q3 2014.
  • DAFNA Capital Management's portfolio value fell 6% quarter-over-quarter to $99.1M.

Based on DAFNA Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.